Adriamycin/cis‐platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland

David S. Alberts, Michael R. Manning, Stanley W. Coulthard, Charles F. Koopmann, Terence S. Herman

Research output: Contribution to journalArticlepeer-review

62 Scopus citations


Five patients were treated with a combination of Adriamycin/cis‐platinum/cyclophosphamide for faradvanced and/or recurrent cancers of the salivary gland. Adriamycin, 40 mg/m2, and cis‐platinum, 50 mg/m2, were given on day 1; cyclophosphamide, 200 mg/m2 daily for four days, was given by mouth on the third to sixth day of each monthly therapy course. Two patients achieved a complete remission, each lasting five months, and the three others had partial remissions from one to seven months (median six months) in duration. Therapy was well tolerated. Severe nausea and vomiting occurred on the first day of therapy but was self‐limited. There was only mild to moderate leukopenia, no significant thrombo‐cytopenia or elevations of serum creatinine, and no evidence of dose‐limiting peripheral neuropathy. Adriamycin/cis‐platinum/cyclophosphamide chemotherapy appears to be effective in the treatment of advanced parotid gland cancers.

Original languageEnglish (US)
Pages (from-to)645-648
Number of pages4
Issue number4
StatePublished - Feb 15 1981
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adriamycin/cis‐platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland'. Together they form a unique fingerprint.

Cite this